Related Experiment Videos
Hodgkin lymphoma: the follow-up of long-term survivors
1Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital, 610 University Avenue, Toronto M5G 2M9, Canada. david.hodgson@rmp.uhn.on.ca
Insights
Long-term management of Hodgkin lymphoma (HL) survivors focuses on addressing late-emerging health issues after successful treatment. Care shifts to minimizing treatment side effects in patients in remission for over five years.
Area of Science:
- Oncology
- Hematology
- Survivorship Care
Background:
- Hodgkin lymphoma (HL) predominantly affects children and young adults.
- Over 80% of HL patients achieve cure, leading to a growing population of long-term survivors.
- Survivors face persistent and late-emerging effects from the disease and its treatment.
Purpose of the Study:
- To outline the long-term medical management strategies for Hodgkin lymphoma survivors.
- To emphasize the shift in follow-up care focus from relapse detection to managing treatment-related late effects.
- To guide care for survivors who are at least 5 years post-therapy without evidence of relapse.
Main Methods:
- Review of current clinical guidelines and literature on Hodgkin lymphoma survivorship.
- Analysis of the transition in medical management priorities for long-term survivors.
- Identification of key late effects and strategies for their mitigation.
Main Results:
- The focus of care for Hodgkin lymphoma survivors transitions significantly 5 years post-therapy.
- Minimizing morbidity from late treatment effects becomes paramount in long-term follow-up.
- Proactive management is essential to improve the quality of life for Hodgkin lymphoma survivors.
Conclusions:
- Long-term medical management of Hodgkin lymphoma survivors requires a specialized approach.
- Care should prioritize the prevention and management of late-emerging treatment toxicities.
- Optimizing survivorship care enhances long-term health outcomes for Hodgkin lymphoma patients.
Abstract:
Hodgkin lymphoma (HL) is a disease that typically strikes children and young adults, with more than 80% of those affected being cured. Consequently, HL survivors can live for decades with the persistent and late-emerging effects of the disease and its treatment. The focus of this article is the long-term medical management of HL survivors, specifically those who are 5 years or more off therapy without evidence of relapse, when the focus of follow-up care shifts from detecting relapse to minimizing the morbidity associated with the late effects of treatment.
